Oncoinvent ASA: Annual Report for 2025

Oslo, Norway, 22 April 2026 - Oncoinvent ASA (ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced the publication of the Annual Report for 2025.

The Board of Oncoinvent ASA has approved the annual accounts for 2025. The financial statements and annual report for the financial year 2025 are attached in European Single Electronic Format (ESEF) and as a PDF file.

The documents are also available in the investors section of the Company’s website: https://www.oncoinvent.com/investors/reports-and-presentation